Elbrit Life Sciences is planning to export prescription drugs and OTC products across the globe. The company’s manufacturing facilities are upgraded and are at various stages of approval at various country regulators. By 2020, our manufacturing facility will be complying with USFDA, UKMHRA and Elbrit will have a significant presence in USA, UK and EU in the prescription generics segment.

Elbrit Life Sciences, is planning to start marketing operations in Nepal, Bhutan, Vietnam and other South East Asian countries and in African continent. Elbrit Life Sciences is planning to introduce solid orals, branded generics, prescription generics, OTC formulations, nutraceuticals to the target markets.

By 2021-22, Elbrit Life Sciences plans to achieve 30% of overall revenues from exports. Elbrit Life Sciences will replicate the same success story across the global market.